Patheon to feature SoluPath at CPhI Japan conference

Published: 6-Jul-2011
Research & Development

SoluPath screening includes non-GMP formulation utilising five different drug delivery modalities


Patheon, a leading provider of contract development and manufacturing services to the global pharmaceutical industry, will feature its paradigm changing SoluPath service offering at the CPhI Conference, which runs from 13 – 15 July 2011 in Osaka, Japan. This fixed price service offering is designed to improve bioavailability of compounds with poor solubility by testing, in parallel, multiple formulations.

SoluPath screening includes non-GMP formulation utilising five different drug delivery modalities: micronisation, nanoparticles, lipid-based solutions, co-solvent solutions SMEDDS/SEDDS, and spray drying. By screening multiple cutting edge technologies in parallel, SoluPath delivers rapid results and identifies the best drug delivery solution to increase bioavailability in human studies.

Patheon’s Dr. Kenji Yamada will talk about the SoluPath process during his presentation on 13 July at 11:30 a.m. in Room A. Patheon representatives will also be available to discuss the company’s new service offering at Booth F14 through the duration of the conference.

  • Companies:
  • Patheon
  • CPhI Japan
See more

You may also like

Manufacturing

Japan produces highest quality APIs, CPhI data says

Read more
Several COVID vaccines are approaching commercial launch in Japan, coinciding with an ongoing biosimilars boom

Trending Articles

  1. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  2. How iPSCs can bridge the translational gap in neuroscience Affecting more than one in three people, neurological disorders have a vast impact on global health while exacting a tremendous cost, reports Dr Max Mirza, Vice President of Neuroscience Drug Discovery at Sygnature Discovery
  3. BioMarin Pharmaceutical expands Cork targeted therapy manufacturing facility with new lab The Irish facility is responsible for the development and commercialisation of therapies that address genetic conditions, and this expansion will allow the company to enhance its approved medicine production capacity
  4. Thermo Fisher Scientific officially opens US oral solid dose testing and R&D facility The company's further expansion in the Bend, Oregon area will assist its pharmaceutical clients in the early development of oral solid dosage (OSD) forms
  5. Concept and Accelero Biostructures accelerate early drug discovery with X-ray crystallography The companies will incorporate their X-ray crystallography and drug discovery technologies to offer clients rapid hit-to-lead drug development

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Manufacturing

Japan produces highest quality APIs, CPhI data says

Several COVID vaccines are approaching commercial launch in Japan, coinciding with an ongoing biosimilars boom
Research & Development

CPhI Japan: Internationalisation reaches new heights

Innovation in the country, driven by structural and and regulatory changes, has promoted both inbound and outbound collaboration
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Inside Patheon’s new flexible pharmaceutical development facilities

In the pharmaceutical sector, flexible facilities are in demand as new niche therapies replace traditional blockbusters. Patheon’s Tony Pidgeon, Process Technology Director, and Louise Hall, PMP, Senior Director, Pharmaceutical Development Services, describe improvements made at the company’s new sterile PDS Suite at its Greenville (NC, USA) site to meet the new trend
Regulatory

Fortress Biotech subsidiary Caelum Biosciences enters biopharmaceutical manufacturing agreement with Patheon

Agreement will support Phase II/III studies of Caelum's CAEL-101 in AL amyloidosis
Manufacturing

Thermo Fisher Scientific to acquire leading CDMO, Patheon

The transaction represents a purchase price of approximately $7.2bn
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Now is the time to outsource the management of outsourcing

More than ever before, specialist expertise is being called upon by the pharma industry – from strategy, supply chain and regulatory boutiques through to one-stop CDMOs that provide the whole spectrum of API development to final product production. Susan Birks talked to Patheon about the trends
Manufacturing

Patheon agrees biologics deal with Inhibrx

Initial development work will focus on establishing platform processes for Inhibrx’s cell lines
Subscribe now